• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Result-oriented remuneration for hospital inpatient care].

作者信息

Lüngen M, Lauterbach K W

机构信息

Institut für Gesundheitsökonomie und Klinische Epidemiologie der Universität zu Köln. Markus, Germany.

出版信息

Gesundheitswesen. 2002 Jan;64(1):46-53. doi: 10.1055/s-2002-19507.

DOI:10.1055/s-2002-19507
PMID:11791202
Abstract

Fee-for-benefit means the adjustment of the reimbursement at the quality of care. Both a bonus and a penalty are possible. It is suggested to measure innovative therapies with outcome parameters and give a bonus as an incentive for quality improvements. Standard therapies should be measured with process parameters and be sanctioned with a penalty when the standards are missed. To determine the extend of the bonus and the penalty, the variable costs of a hospital could be used as a reference. Therefore a penalty should not exceed approximately 25 % of the reimbursement. The costs for the introduction and administration of the fee-for-benefit reimbursement must be seen in the context of the necessary improvement of quality insurance in per-case reimbursement with DRG (Diagnosis-Related Groups) in Germany. Related to the incidence of preventable adverse events and the additional costs of poor-quality outcome evaluated from studies fee-for-benefit will be cost-effective by avoiding every sixth adverse event. German legislation allows fee-for-benefit only in small model projects or local integrated networks. It is recommended to allow an optional opening of negotiations between hospitals and sickness funds for fee-for-benefit elements. A pilot study should evaluate the incidence and cost of preventable adverse events in Germany.

摘要

相似文献

1
[Result-oriented remuneration for hospital inpatient care].
Gesundheitswesen. 2002 Jan;64(1):46-53. doi: 10.1055/s-2002-19507.
2
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
3
[Introduction of the DRG system from the point of view of private health insurers].从私立健康保险公司的角度看疾病诊断相关分组(DRG)系统的引入
Z Arztl Fortbild Qualitatssich. 2002 Aug;96(8):505-13.
4
[Evaluating the first German diagnosis-related groups (G-DRG) in cardiological patients: problems in the correct medical and economic grouping].[评估德国首个心脏病患者诊断相关分组(G-DRG):正确医学和经济分组中的问题]
Z Kardiol. 2003 Jul;92(7):581-94. doi: 10.1007/s00392-003-0957-9.
5
[Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].[干细胞移植及特定化疗病例成本的自下而上分析]
Klin Padiatr. 2003 May-Jun;215(3):179-84. doi: 10.1055/s-2003-39379.
6
[What would happen... if the physician were paid according to treatment success?].如果根据治疗效果来支付医生薪酬,会发生什么情况?
MMW Fortschr Med. 2006 Sep 14;148(37):65.
7
[Evaluation of Federal Health Insurance process data as instrument for structural and quality analysis of inpatient care].
Gesundheitswesen. 1997 Jan;59(1):10-6.
8
[Costs for acute, stationary treatment of polytrauma patients].[多发伤患者急性、固定治疗的费用]
Unfallchirurg. 2002 Nov;105(11):1043-8. doi: 10.1007/s00113-002-0524-2.
9
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
10
[Remarks on the introduction of the German Diagnosis-Related Groups (DRGs) for the specialty of urology].[关于德国泌尿外科专业诊断相关分组(DRGs)引入的说明]
Urologe A. 2003 Apr;42(4):496-504. doi: 10.1007/s00120-003-0327-2. Epub 2003 Mar 20.

引用本文的文献

1
[Quality management in ophthalmology. Putting it into practice in the clinical routine].
Ophthalmologe. 2004 Oct;101(10):973-81. doi: 10.1007/s00347-004-1081-6.